300595.SHE Autek China Inc
- Market cap
- CNY 9.48B
- P/E
- 21.6x
- P/B
- 1.77x
- ROE
- 10.3%
- Dividend yield
- 2.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300595.SHE undervalued?
Graham number300595.SHE trades 30.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Autek China Inc fundamental analysis
No fundamental analysis for Autek China Inc yet.
Autek China Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Autek China Inc
Autek China Inc. engages in the research and development, production, and sale of optometry products and related supporting products in China. The company offers rigid contact lenses, rigid lens care products, myopia control products other than rigid glasses, visual function training products, dry eye/eye strain/presbyopia/accommodative hypoplasia treatment products, and eye health products. It also provides ophthalmic and optometry medical devices. Autek China Inc. was inco…
Full company profileAutek China Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Autek China Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 235M | 312M | 458M | 647M | 871M | 1.30B | 1.53B | 1.74B | 1.81B | 1.85B | 1.85B |
| Gross Profit | 174M | 238M | 357M | 507M | 684M | 993M | 1.17B | 1.30B | 1.33B | 1.21B | 1.32B |
| Operating Income | 131M | 179M | 245M | 334M | 474M | 685M | 799M | 856M | 739M | 623M | 663M |
| EBITDA | 128M | 170M | 223M | 305M | 445M | 634M | 733M | 785M | 738M | 623M | 702M |
| Net Income | 114M | 151M | 216M | 307M | 433M | 555M | 624M | 667M | 572M | 480M | 537M |
| EPS | 0.18 | 0.18 | 0.26 | 0.36 | 0.51 | 0.65 | 0.72 | 0.75 | 0.64 | 0.54 | 0.60 |
| Balance Sheet | |||||||||||
| Total Assets | 358M | 923M | 1.23B | 1.61B | 2.21B | 2.97B | 5.12B | 5.52B | 6.03B | 6.30B | 6.35B |
| Total Liabilities | 41.6M | 110M | 145M | 168M | 222M | 436M | 523M | 808M | 887M | 849M | 731M |
| Shareholders' Equity | 311M | 805M | 1.02B | 1.33B | 1.75B | 2.22B | 4.23B | 4.35B | 4.70B | 4.91B | 5.20B |
| Cash & Short-term Investments | 230M | 166M | 178M | 461M | 1.31B | 1.35B | 2.29B | 3.17B | 2.01B | 3.20B | 832M |
| Total Debt | - | 42.6M | 48.7M | 200K | 1.00M | 164M | 225M | 183M | 202M | 308M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 109M | 145M | 149M | 275M | 381M | 630M | 652M | 723M | 685M | 827M | - |
| Capital Expenditure | 28.6M | 62.8M | 35.3M | 57.1M | 94.4M | 138M | 129M | 198M | 207M | 121M | 64.7M |
| Free Cash Flow | 80.2M | 81.9M | 113M | 218M | 287M | 492M | 522M | 525M | 478M | 707M | 621M |
| Ratios | |||||||||||
| ROE | 36.6% | 18.7% | 21.1% | 23.1% | 24.7% | 25.0% | 14.7% | 15.3% | 12.2% | 9.8% | 10.3% |
| ROA | 31.9% | 16.4% | 17.6% | 19.1% | 19.6% | 18.7% | 12.2% | 12.1% | 9.5% | 7.6% | 8.5% |
| Net Profit Margin | 48.5% | 48.4% | 47.2% | 47.4% | 49.8% | 42.8% | 40.9% | 38.4% | 31.6% | 25.9% | 29.0% |
| Debt to Equity | - | 0.05x | 0.05x | 0.00x | 0.00x | 0.07x | 0.05x | 0.04x | 0.04x | 0.06x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Autek China Inc dividends
- Dividend yield
- 2.65%
- Forward dividend
- 0.18 CNY
- Payout ratio
- 52.3%
- Ex-dividend date
- Oct 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 251M | 0.28 | 52.3% |
| 2024 | CNY 203M | 0.23 | 35.5% |
| 2023 | CNY 125M | 0.14 | 18.8% |
| 2022 | CNY 124M | 0.14 | 19.9% |
| 2021 | CNY 125M | 0.15 | 22.4% |
| 2020 | CNY 40.5M | 0.05 | 9.3% |
| 2019 | CNY 31.4M | 0.04 | 10.2% |
| 2018 | CNY 25.1M | 0.03 | 11.6% |
| 2017 | CNY 23.8M | 0.03 | 15.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4175:1 on May 21, 2021.
Who owns Autek China Inc
- Insiders 48.49%
- Institutions 3.84%
- Public & others 47.68%
- Shares outstanding 894M
- Free float 466M
Autek China Inc company profile
- Company name
- Autek China Inc
- Ticker
- 300595.SHE
- ISIN
- CNE100002MR0
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,752
- Fiscal year end
- December
- Address
- No. 4899 Wangjiang West Road, Hefei, China, 230088
- Phone
- 86 55 16295 2208
- Website
- orthok.cn
About Autek China Inc
Autek China Inc. engages in the research and development, production, and sale of optometry products and related supporting products in China. The company offers rigid contact lenses, rigid lens care products, myopia control products other than rigid glasses, visual function training products, dry eye/eye strain/presbyopia/accommodative hypoplasia treatment products, and eye health products. It also provides ophthalmic and optometry medical devices. Autek China Inc. was incorporated in 2000 and is based in Hefei, China.
Autek China Inc management
8- Mr. Yuequn TaoGM & Chairman · born 1960
- Mr. Lizhi WeiCFO & Non-Independent Director · born 1982
- Ms. Xianmei ShiDeputy GM, Secretary, Operations Director & Non-Independent Director · born 1974
- Ms. Zhiying FuDeputy General Manager · born 1983
- Mr. Zhe ZhuDeputy General Manager · born 1965
- Mr. Yongzhan XiaoDeputy General Manager · born 1970
- Mr. Guoxin DongDeputy General Manager · born 1968
- Chang WangAccounting Supervisor